生物学的製剤に効果不十分は強直性脊椎炎患者におけるウパダシチニブの有効性と安全性: フェーズIII試験オープンラベル延長試験の1年結果
Arthritis Res Ther 2023; 2023;18;25(1):172 doi 10.1186/s13075-023-03128-1
The efficacy and safety of updacitinib in bDMARD-IR patients with AS were sustained through to one year in an open-label extension of the SELECT-AXIS 2 study.